Trial Profile
Gene Transfer For Patients With Sickle Cell Disease Using A Gamma Globin Lentivirus Vector: An Open-Label Phase 1 / 2 Pilot Study
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 17 Jan 2024
Price :
$35
*
At a glance
- Drugs ARU 1801 (Primary) ; Melphalan
- Indications Sickle cell anaemia
- Focus Adverse reactions; Therapeutic Use
- Acronyms MOMENTUM
- 18 Jul 2023 Planned End Date changed from 1 Jun 2035 to 1 Jul 2038.
- 18 Jul 2023 Planned primary completion date changed from 1 Jun 2023 to 14 Jul 2037.
- 18 Jul 2022 Status changed from recruiting to active, no longer recruiting.